Navigation Links
SEMBIOSYS ISSUED KEY U.S. PATENT FOR THE PRODUCTION OF APOLIPOPROTEINS IN PLANTS
Date:9/1/2010

CALGARY, Sept. 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS) today announced that the United States Patent and Trade Mark Office has granted the Company U.S. patent 7,786,352 entitled "Methods for the Production of Apolipoproteins in Transgenic Plants". The granted patent claims include the methods for the expression of apolipoprotein (Apo) in plants, including Apo AI(Milano), the introduction of related chimeric nucleic acid into plant cells and producing plant cells capable of growing into mature plants which produce seeds that express apolipoprotein. This patent is key to successfully commercializing plant made and seed expressed Apo AI(Milano).

The intent of the Company's global patent strategy is to own exclusive rights to transgenic production of biosimilar drugs and novel drug candidates like Apo AI(Milano) in select plant and plant-seed lines and to be able to make such drugs in a scalable and affordable manner. In doing so, the Company believes it is rapidly becoming a highly attractive partner to large pharma partners looking to enter these markets with a differentiated and patent protected manufacturing cost structure.

"The issuance of this patent and the continuing success of our Apo AI(Milano) development strengthens the program as we advance through the partnership process with interested parties. This newly granted patent significantly enhances the value of our development and commercialization program for Apo AI(Milano), our next-generation cardiovascular drug candidate with blockbuster potential," said James Szarko, President and CEO of SemBioSys. "Apo AI(Milano) has the potential to address large unmet medical needs as an acute treatment for atherosclerosis or arterial blockage caused by plaque build-up on arterial walls, which leads to stroke and heart attacks. Our plant-seed based expression system for the production of Apo, biosimilar drugs and potentially other novel pharmaceutical drug candidates is a truly disr
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
2. SemBioSys begins phase I/II trial of insulin produced in plant seeds
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. SemBioSys announces senior management changes
5. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
6. SemBioSys provides update on insulin program
7. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
8. SemBioSys plant-derived Apo AI(Milano) demonstrates encouraging biologic activity in seven preclinical models
9. Data for SemBioSys insulin to be presented at the American Diabetes Associations 69th Scientific Sessions
10. SemBioSys provides an update on Botaneco
11. SemBioSys announces third quarter 2009 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... September 30, 2014 Award winning ... announces four new-hosted collaboration bundles that combine ... high quality conferencing experiences for low, flat rate ... choose from, businesses have optimized solutions to meet ... include audio only minutes (1K, 5K, 10K ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific ... 2014 Summary Global Markets Direct,s, ,Pacific ... 2014, provides an overview of the Pacific Northwest ... This report provides comprehensive information on the current ... complete with comparative analysis at various stages, therapeutics ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
Breaking Biology Technology:SoundConnect Launches New Audio, Web and Video Bundles 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... 5 , - Data Presented ... York , ThromboGenics NV (Euronext Brussels: ... innovative medicines for eye,disease, vascular disease and cancer, today announces ... the treatment of,Diabetic Macular Edema (MIVI II DME). The data ...
... , LA JOLLA, Calif., Oct. 5 Transdel Pharmaceuticals, Inc. ... a conference call and audio webcast on Tuesday, October 6, ... of its Phase 3 clinical study for Ketotransdel®, a topical ... A press release will be issued on Tuesday, October 6, ...
... Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported ... bavituximab in combination with carboplatin and paclitaxel in patients ... reported from the initial cohort of 21 patients in ... patients with locally advanced or metastatic NSCLC achieved an ...
Cached Biology Technology:ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 2ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 3ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) 4Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 2Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R) 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 2Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 3Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial 4
(Date:10/1/2014)... researchers hope to take a healthy salad up a ... of breast cancer in leafy greens. , "In the ... either by eating the salad or making a pill ... of biomedical engineering at Case Western Reserve School of ... G. Komen breast cancer organization is funding the research ...
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... WASHINGTON, D.C., September 30, 2014--Sea monkeys have captured the ... of their easily observable life cycle -- sold as ... and mate given little more than a tank of ... a shorter-term pattern: Like other zooplankton, brine shrimp vertically ... conditions, coming closer to the surface at night and ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2
... available in German . ... animal behaviour that is subject to annual rhythms is controlled by ... time, in many cases it is still unclear how far genes ... also applied to the common buzzard and its migration from parental ...
... , This news release is available in ... are bad at getting a grip on collective risks. Climate change ... so far not led to specific measures. The reason for this ... than to investing in future quality of life. Therefore, ...
... physicians and biologists alike - even though it is well-established ... stages, immobility can all be traced back to the death ... neuron. The underlying cause of this cellular death is a ... external factors, most of the details of which are well-known. ...
Cached Biology News:The molecular clock of the common buzzard 2People don't put a high value on climate protection 2People don't put a high value on climate protection 3PD map: Putting together the pieces of the Parkinson's puzzle 2PD map: Putting together the pieces of the Parkinson's puzzle 3
RAT ANTI MOUSE METALLOPHILIC MACROPHAGES...
Request Info...
Agarase cleaves agarose to neoagaro-oligosaccharides, and is used for,quantitative, gentle recovery of DNA from low melting point agarose....
Request Info...
Biology Products: